nach oben

Erschienen in:

2022 | OriginalPaper | Buchkapitel

Controlled Delivery and Reduced Side Effects of Anticancer Drugs Complexed with Polymeric Nanocarrier

verfasst von : Lesya Kobylinska, Nataliya Mitina, Alexander Zaichenko, Rostyslav Stoika

Erschienen in: Biomedical Nanomaterials

Verlag: Springer International Publishing

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

A big challenge in the development of pharmaceutical drugs is to eliminate or at least reduce the side effects of highly active drugs, especially the antitumor agents demonstrating general toxicity in the body that significantly restricts their use. An efficient way to overcome this problem is to use a multifunctional nanocarrier of the drug that will allow the toxic antitumor agent to act at the site of its delivery to targeted cells in specific organs or tissues. The use of nanoparticles permits to optimize efficiency, minimize side effects, and improve cancer chemotherapy. Polymeric nanoparticles possess a huge potential in cancer chemotherapy, being one of the most widely tested nano-platforms and offering more effective and less toxic options to patients. Nanoconjugates can influence apoptotic mechanisms and enhance the cytotoxic action of drugs conjugated to the nanoparticles. The side effects of such action in the organism strongly depend upon the balance between the reactive oxygen species and the activity of the antioxidant system in the targeted cells. Drug delivery systems provide prolonged circulation of drug in blood, are able to accumulate in the pathological loci, and are capable of transferring active drug molecules effectively into specific cells and their organelles. Thus, the conjugation of the antitumor drug with a polymeric nanocarrier and application of drug in the form of a stable drug delivery system can reduce its general toxicity in the organism, compared with drug action in free form.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Vorheriges Kapitel Magnetic Iron Oxide Particles for Theranostics

Nächstes Kapitel Nano- and Microparticles and Their Role in Inflammation and Immune Response: Focus on Neutrophil Extracellular Traps

Bamrungsap, S., Zhao, Z., Chen, T., Wang, L., Li, C., Fu, T., & Tan, W. (2012). Nanotechnology in therapeutics: A focus on nanoparticles as a drug delivery system. Nanomedicine, 7(8), 1253–1271. https://doi.org/10.2217/nnm.12.87CrossRef

Barraud, L., Merle, P., Soma, E., Lefrançois, L., Guerret, S., Chevallier, M., Dubernet, C., et al. (2005). Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. Journal of Hepatology, 42(5), 736–743. https://doi.org/10.1016/j.jhep.2004.12.035CrossRef

Beechinor, R., & Gonzalez, D. (2017). Book review: Introduction to drug disposition and pharmacokinetics. Clinical Pharmacology & Therapeutics, 102(6), 893–893. https://doi.org/10.1002/cpt.806CrossRef

Bilia, A., Piazzini, V., Risaliti, L., Vanti, G., Casamonti, M., Wang, M., & Bergonzi, M. (2019). Nanocarriers: A successful tool to increase solubility, stability and optimise bioefficacy of natural constituents. Current Medicinal Chemistry, 26(24), 4631–4656. https://doi.org/10.2174/0929867325666181101110050CrossRef

Boyd, M., & Paull, K. (1995). Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Development Research, 34(2), 91–109. https://doi.org/10.1002/ddr.430340203CrossRef

Brigger, I., Dubernet, C., & Couvreur, P. (2012). Nanoparticles in cancer therapy and diagnosis. Advanced Drug Delivery Reviews, 64, 24–36. https://doi.org/10.1016/j.addr.2012.09.006CrossRef

Bunker, A. (2012). Poly(ethylene glycol) in drug delivery, why does it work, and can we do better? All atom molecular dynamics simulation provides some answers. Physics Procedia, 34, 24–33. https://doi.org/10.1016/j.phpro.2012.05.004CrossRef

Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., et al. (2011). Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nature Nanotechnology, 6(12), 815–823. https://doi.org/10.1038/nnano.2011.166CrossRef

Couvreur, P., Kante, B., Roland, M., & Speiser, P. (1979). Adsorption of antineoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum. Journal of Pharmaceutical Sciences, 68(12), 1521–1524. https://doi.org/10.1002/jps.2600681215CrossRef

de Jong. (2008). Drug delivery and nanoparticles: Applications and hazards. International Journal of Nanomedicine, 133. https://doi.org/10.2147/ijn.s596

Dutta, R. (2007). Drug carriers in pharmaceutical design: Promises and progress. Current Pharmaceutical Design, 13(7), 761–769. https://doi.org/10.2174/138161207780249119CrossRef

Feng, R., Zhu, W., Teng, F., Liu, N., Yang, F., Meng, N., & Song, Z. (2015). Poly(ethylene glycol) amphiphilic copolymer for anticancer drugs delivery. Anti-Cancer Agents in Medicinal Chemistry, 15(2), 176–188. https://doi.org/10.2174/1871520614666141124102347CrossRef

Finiuk, N., Boiko, N., Klyuchivska, O., Коbylinska, L., Kril, I., Zimenkovsky, B., et al. (2017). 4-Thiazolidinone derivative Les-3833 effectively inhibits viability of human melanoma cells through activating apoptotic mechanisms. Croatian Medical Journal, 58(2), 129–139. https://doi.org/10.3325/cmj.2017.58.129CrossRef

Gong, J., Chen, M., Zheng, Y., Wang, S., & Wang, Y. (2012). Polymeric micelles drug delivery system in oncology. Journal of Controlled Release, 159(3), 312–323. https://doi.org/10.1016/j.jconrel.2011.12.012CrossRef

Goormaghtigh, E., Chatelain, P., Caspers, J., & Ruysschaert, J. (1980). Evidence of a specific complex between adriamycin and negatively-charged phospholipids. Biochimica et Biophysica Acta (BBA) – Biomembranes, 597(1), 1–14. https://doi.org/10.1016/0005-2736(80)90145-5CrossRef

Hamaguchi, T., Doi, T., Eguchi-Nakajima, T., Kato, K., Yamada, Y., Shimada, Y., et al. (2010). Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clinical Cancer Research, 16(20), 5058–5066. https://doi.org/10.1158/1078-0432.ccr-10-0387CrossRef

Hamaguchi, T., Kato, K., Yasui, H., Morizane, C., Ikeda, M., Ueno, H., et al. (2007). A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. British Journal of Cancer, 97(2), 170–176. https://doi.org/10.1038/sj.bjc.6603855CrossRef

Havrylyuk, D., Zimenkovsky, B., Vasylenko, O., Gzella, A., & Lesyk, R. (2012). Synthesis of new 4-thiazolidinone-, pyrazoline-, and isatin-based conjugates with promising antitumor activity. Journal of Medicinal Chemistry, 55(20), 8630–8641. https://doi.org/10.1021/jm300789gCrossRef

Hillaireau, H., & Couvreur, P. (2009). Nanocarriers’ entry into the cell: Relevance to drug delivery. Cellular and Molecular Life Sciences, 66(17), 2873–2896. https://doi.org/10.1007/s00018-009-0053-zCrossRef

Hu, C., Aryal, S., & Zhang, L. (2010). Nanoparticle-assisted combination therapies for effective cancer treatment. Therapeutic Delivery, 1(2), 323–334. https://doi.org/10.4155/tde.10.13CrossRef

Iwamoto, T. (2013). Clinical application of drug delivery systems in cancer chemotherapy: Review of the efficacy and side effects of approved drugs. Biological and Pharmaceutical Bulletin, 36(5), 715–718. https://doi.org/10.1248/bpb.b12-01102CrossRef

Joshi, M., Sodhi, K., Pandey, R., Singh, J., & Goyal, S. (2015). Doxorubicin-induced cardiotoxicity. International Journal of Basic & Clinical Pharmacology, 4(1), 6. https://doi.org/10.5455/2319-2003.ijbcp20150203CrossRef

Jabir, N. R., Tabrez, S., Ashraf, G. M., Shakil, S., Damanhouri, G. A., & Kamal, M. A. (2012, 4391). Nanotechnology-based approaches in anticancer research. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s33838

Kato, K., Chin, K., Yoshikawa, T., Yamaguchi, K., Tsuji, Y., Esaki, T., et al. (2011). Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Investigational New Drugs, 30(4), 1621–1627. https://doi.org/10.1007/s10637-011-9709-2CrossRef

Kim, R., Tanabe, K., Uchida, Y., Emi, M., Inoue, H., & Toge, T. (2002). Current status of the molecular mechanisms of anticancer drug-induced apoptosis. Cancer Chemotherapy and Pharmacology, 50(5), 343–352. https://doi.org/10.1007/s00280-002-0522-7CrossRef

Kobylinska, L., Boiko, N., Panchuk, R., Grytsyna, I., Klyuchivska, O., Biletska, L., et al. (2016). Putative anticancer potential of novel 4-thiazolidinone derivatives: Cytotoxicity toward rat C6 glioma in vitro and correlation of general toxicity with the balance of free radical oxidation in rats. Croatian Medical Journal, 57(2), 151–163. https://doi.org/10.3325/cmj.2016.57.151CrossRef

Kоbylinska, L., Havrylyuk, D., Mitina, N., et al. (2014). Study of rat blood serum biochemical indicators of cardiotoxic action of novel antitumor 4-thiazolidinone derivatives and doxorubicin in complexes with polyethylenglycol-containing polymeric carrier in the rat blood serum. The Ukrainian Biochemical Journal, 86(6), 84–95. https://doi.org/10.15407/ubj86.06.084CrossRef

Kоbylinska, L., Havrylyuk, D., Mitina, N., et al. (2016). Biochemical indicators of nephrotoxicity in blood serum of rats treated with novel 4-thiazolidinone derivatives or their complexes with polyethylene glycol-containing nanoscale polymeric carrier. The Ukrainian Biochemical Journal, 88(1), 51–60. https://doi.org/10.15407/ubj88.01.051CrossRef

Kоbylinska, L., Havrylyuk, D., Ryabtseva, А., Mitina, N., Zаichenko, О., Lesyk, R., et al. (2015). Biochemical indicators of hepatotoxicity in blood serum of rats under the effect. The Ukrainian Biochemical Journal, 87(2), 122–132. https://doi.org/10.15407/ubj87.02.122CrossRef

Kobylinska, L., Ivasechko, I., Skorokhyd, N., Panchuk, R., Riabtseva, A., Mitina, N., et al. (2019). Enhanced proapoptotic effects of water dispersed complexes of 4-thiazolidinone-based chemotherapeutics with a PEG-containing polymeric nanocarrier. Nanoscale Research Letters, 14(1). https://doi.org/10.1186/s11671-019-2945-7

Kobylinska, L., Lozynskii, A., Lesyk, R., Stoika, R., & Vari, S. (2020). Biodistribution and anticancer characteristics of Les-3833, a novel 4-thiazolidinone-based lead compound. Scientia Pharmaceutica, 88(2), 18. https://doi.org/10.3390/scipharm88020018CrossRef

Kobylinska, L., Patereha, I., Finiuk, N., Mitina, N., Riabtseva, A., Kotsyumbas, I., et al. (2018). Comb-like PEG-containing polymeric composition as low toxic drug nanocarrier. Cancer Nanotechnology, 9(1). https://doi.org/10.1186/s12645-018-0045-5

Kobylinska, L., Skorohyd, N., Klyuchivska, O., Mitina, N., Zaichenko, A., Lesyk, R., et al. (2018). Increased antitumor efficiency and reduced negative side effects in laboratory mice of 4-thiazolidinone derivatives in complexes with PEG-containing polymeric nanocarrier. Biopolymers and Cell, 34(4), 313–328. https://doi.org/10.7124/bc.000985CrossRef

Kwon, G. (2003). Polymeric micelles for delivery of poorly water-soluble compounds. Critical Reviews in Therapeutic Drug Carrier Systems, 20(5), 357–403. https://doi.org/10.1615/critrevtherdrugcarriersyst.v20.i5.20CrossRef

Kwon, G., & Kataoka, K. (2012). Block copolymer micelles as long-circulating drug vehicles. Advanced Drug Delivery Reviews, 64, 237–245. https://doi.org/10.1016/j.addr.2012.09.016CrossRef

Lammers, T., Kiessling, F., Hennink, W., & Storm, G. (2012). Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. Journal of Controlled Release, 161(2), 175–187. https://doi.org/10.1016/j.jconrel.2011.09.063CrossRef

Langer, R. (1999). Selected advances in drug delivery and tissue engineering. Journal of Controlled Release, 62(1–2), 7–11. https://doi.org/10.1016/s0168-3659(99)00057-7CrossRef

Langer, R., & Folkman, J. (1976). Polymers for the sustained release of proteins and other macromolecules. Nature, 263(5580), 797–800. https://doi.org/10.1038/263797a0CrossRef

Lee, S., Yun, M., Jeong, S., In, C., Kim, J., Seo, M., et al. (2011). Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system. Journal of Controlled Release, 155(2), 262–271. https://doi.org/10.1016/j.jconrel.2011.06.012CrossRef

Li, Y. (2003). Nanoparticles bearing polyethyleneglycol-coupled transferrin as gene carriers: Preparation and in vitro evaluation. International Journal of Pharmaceutics, 259(1–2), 93–101. https://doi.org/10.1016/s0378-5173(03)00211-4CrossRef

Liu, D., & Auguste, D. (2015). Cancer targeted therapeutics: From molecules to drug delivery vehicles. Journal of Controlled Release, 219, 632–643. https://doi.org/10.1016/j.jconrel.2015.08.041CrossRef

Liu, Z., Jiao, Y., Wang, Y., Zhou, C., & Zhang, Z. (2008). Polysaccharides-based nanoparticles as drug delivery systems. Advanced Drug Delivery Reviews, 60(15), 1650–1662. https://doi.org/10.1016/j.addr.2008.09.001CrossRef

Lu, Y., & Park, K. (2013). Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. International Journal of Pharmaceutics, 453(1), 198–214. https://doi.org/10.1016/j.ijpharm.2012.08.042CrossRef

Ma, P. (2013). Paclitaxel nano-delivery systems: A comprehensive review. Journal of Nanomedicine & Nanotechnology, 04(02). https://doi.org/10.4172/2157-7439.1000164

Marenberg, B. (2004). FDA issues final rule on patent listing requirements and 30-month stays of approval following submission of abbreviated new drug applications. Biotechnology Law Report, 23(1), 48–51. https://doi.org/10.1089/073003104322838240CrossRef

Matés, J., & Sánchez-Jiménez, F. (2000). Role of reactive oxygen species in apoptosis: Implications for cancer therapy. The International Journal of Biochemistry & Cell Biology, 32(2), 157–170. https://doi.org/10.1016/s1357-2725(99)00088-6CrossRef

Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., et al. (2004). Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. British Journal of Cancer, 91(10), 1775–1781. https://doi.org/10.1038/sj.bjc.6602204CrossRef

Milane, L., Duan, Z., & Amiji M. (2011) Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS One. 6(9): e24075. https://doi.org/10.1371/journal.pone.0024075

Min, Y., Caster, J., Eblan, M., & Wang, A. (2015). Clinical translation of nanomedicine. Chemical Reviews, 115(19), 11147–11190. https://doi.org/10.1021/acs.chemrev.5b00116CrossRef

Mishra, P., Nayak, B., & Dey, R. (2016). PEGylation in anti-cancer therapy: An overview. Asian Journal of Pharmaceutical Sciences, 11(3), 337–348. https://doi.org/10.1016/j.ajps.2015.08.011CrossRef

Mitra, S., Gaur, U., Ghosh, P., & Maitra, A. (2001). Tumour targeted delivery of encapsulated dextran–doxorubicin conjugate using chitosan nanoparticles as carrier. Journal of Controlled Release, 74(1–3), 317–323. https://doi.org/10.1016/s0168-3659(01)00342-xCrossRef

Mitry, M., & Edwards, J. (2016). Doxorubicin induced heart failure: Phenotype and molecular mechanisms. IJC Heart & Vasculature, 10, 17–24. https://doi.org/10.1016/j.ijcha.2015.11.004CrossRef

Narvekar, M., Xue, H., Eoh, J., & Wong, H. (2014). Nanocarrier for poorly water-soluble anticancer drugs—Barriers of translation and solutions. AAPS PharmSciTech, 15(4), 822–833. https://doi.org/10.1208/s12249-014-0107-xCrossRef

Nath Roy, D., Goswami, R., & Pal, A. (2016). Nanomaterial and toxicity: What can proteomics tell us about the nanotoxicology? Xenobiotica, 47(7), 632–643. https://doi.org/10.1080/00498254.2016.1205762CrossRef

Naughton, C. A. (1984). Drug-induced nephrotoxicity. Reactions, 94(1), 11–12. https://doi.org/10.1007/bf03273412CrossRef

Navarro, V., & Senior, J. (2006). Drug-related hepatotoxicity. New England Journal of Medicine, 354(7), 731–739. https://doi.org/10.1056/nejmra052270CrossRef

Novel Drug Approvals for 2020. U.S. Food and Drug Administration [cited 22 January 2021]. Available from: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

Onishi, H., Machida, Y., & Machida, Y. (2003). Antitumor properties of irinotecan-containing nanoparticles prepared using poly(DL-lactic acid) and poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol). Biological & Pharmaceutical Bulletin, 26(1), 116–119. https://doi.org/10.1248/bpb.26.116CrossRef

Otsuka, H., Nagasaki, Y., & Kataoka, K. (2003). PEGylated nanoparticles for biological and pharmaceutical applications. Advanced Drug Delivery Reviews, 55(3), 403–419. https://doi.org/10.1016/s0169-409x(02)00226-0CrossRef

Park, K., Lee, G., Kim, Y., Yu, M., Park, R., Kim, I., et al. (2006). Heparin–deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. Journal of Controlled Release, 114(3), 300–306. https://doi.org/10.1016/j.jconrel.2006.05.017CrossRef

Pérez-Herrero, E., & Fernández-Medarde, A. (2015). Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. European Journal of Pharmaceutics and Biopharmaceutics, 93, 52–79. https://doi.org/10.1016/j.ejpb.2015.03.018CrossRef

Perry, M., & Doll, D. (2012). Perry's the chemotherapy source book. Lipincott Williams & Wilkins.

Plummer, R., Wilson, R., Calvert, H., Boddy, A., Griffin, M., Sludden, J., et al. (2011). A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. British Journal of Cancer, 104(4), 593–598. https://doi.org/10.1038/bjc.2011.6CrossRef

Rahman, A., Fumagalli, A., Barbieri, B., Schein, P., & Casazza, A. (1986). Antitumor and toxicity evaluation of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Chemotherapy and Pharmacology, 16(1). https://doi.org/10.1007/bf00255281

Ramadori, G., & Cameron, S. (2010). Effects of systemic chemotherapy on the liver. Annals of Hepatology, 9(2), 133–143. https://doi.org/10.1016/s1665-2681(19)31651-5CrossRef

Ravi Kumar, M., & Kumar, N. (2001). Polymeric controlled drug-delivery systems: Perspective issues and opportunities. Drug Development and Industrial Pharmacy, 27(1), 1–30. https://doi.org/10.1081/ddc-100000124CrossRef

Riabtseva, A., Mitina, N., Boiko, N., Garasevich, S., Yanchuk, I., Stoika, R., et al. (2012). Structural and colloidal-chemical characteristics of nanosized drug delivery systems based on pegylated comb-like carriers. Chemistry & Chemical Technology, 6(3), 291–295. https://doi.org/10.23939/chcht06.03.291CrossRef

Rollerova, E., Tulinska, J., Liskova, A., Kuricova, M., Kovriznych, J., Mlynarcikova, A., et al. (2015). Titanium dioxide nanoparticles: Some aspects of toxicity/focus on the development. Endocrine Regulations, 49(02), 97–112. https://doi.org/10.4149/endo_2015_02_97CrossRef

Sahoo, S., & Labhasetwar, V. (2003). Nanotech approaches to drug delivery and imaging. Drug Discovery Today, 8(24), 1112–1120. https://doi.org/10.1016/s1359-6446(03)02903-9CrossRef

Savjani, K., Gajjar, A., & Savjani, J. (2012). Drug solubility: Importance and enhancement techniques. ISRN Pharmaceutics, 2012, 1–10. https://doi.org/10.5402/2012/195727CrossRef

Sharifi, S., Barar, J., Hejazi, M., & Samadi, N. (2015). Doxorubicin changes Bax/Bcl-xL ratio, caspase-8 and 9 in breast cancer cells. Advanced Pharmaceutical Bulletin, 5(3), 351–359. https://doi.org/10.15171/apb.2015.049CrossRef

Shi, Y., Moon, M., Dawood, S., McManus, B., & Liu, P. (2011). Mechanisms and management of doxorubicin cardiotoxicity. Herz, 36(4), 296–305. https://doi.org/10.1007/s00059-011-3470-3CrossRef

Shoemaker, R. (2006). The NCI60 human tumour cell line anticancer drug screen. Nature Reviews Cancer, 6(10), 813–823. https://doi.org/10.1038/nrc1951CrossRef

Soppimath, K., Aminabhavi, T., Kulkarni, A., & Rudzinski, W. (2001). Biodegradable polymeric nanoparticles as drug delivery devices. Journal of Controlled Release, 70(1–2), 1–20. https://doi.org/10.1016/s0168-3659(00)00339-4CrossRef

Sullivan, L., & Chandel, N. (2014). Mitochondrial reactive oxygen species and cancer. Cancer & Metabolism, 2(1). https://doi.org/10.1186/2049-3002-2-17

Talelli, M., Rijcken, C., Hennink, W., & Lammers, T. (2012). Polymeric micelles for cancer therapy: 3 C’s to enhance efficacy. Current Opinion in Solid State and Materials Science, 16(6), 302–309. https://doi.org/10.1016/j.cossms.2012.10.003CrossRef

Talukder, R., Reed, C., Dürig, T., & Hussain, M. (2011). Dissolution and solid-state characterization of poorly water-soluble drugs in the presence of a hydrophilic carrier. AAPS PharmSciTech, 12(4), 1227–1233. https://doi.org/10.1208/s12249-011-9697-8CrossRef

Tang, M., Lei, L., Guo, S., & Huang, W. (2010). Recent progress in nanotechnology for cancer therapy. Chinese Journal of Cancer, 29(9), 775–780. https://doi.org/10.5732/cjc.010.10075CrossRef

Tomao, S. (2009). Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. International Journal of Nanomedicine, 99. https://doi.org/10.2147/ijn.s3061

Tong, R., & Cheng, J. (2007). Anticancer polymeric nanomedicines. Polymer Reviews, 47(3), 345–381. https://doi.org/10.1080/15583720701455079CrossRef

Torchilin, V. (2001). Structure and design of polymeric surfactant-based drug delivery systems. Journal of Controlled Release, 73(2–3), 137–172. https://doi.org/10.1016/s0168-3659(01)00299-1CrossRef

Torchilin, V. (2007). Nanocarriers. Pharmaceutical Research, 24(12), 2333–2334. https://doi.org/10.1007/s11095-007-9463-5CrossRef

Ulbrich, K. (2004). Polymeric anticancer drugs with pH-controlled activation. Advanced Drug Delivery Reviews, 56(7), 1023–1050. https://doi.org/10.1016/j.addr.2003.10.040CrossRef

Wang, L., Du, J., Zhou, Y., & Wang, Y. (2017). Safety of nanosuspensions in drug delivery. Nanomedicine: Nanotechnology, Biology and Medicine, 13(2), 455–469. https://doi.org/10.1016/j.nano.2016.08.007CrossRef

Wang, X., Wang, Y., Chen, Z., & Shin, D. (2009). Advances of cancer therapy by nanotechnology. Cancer Research and Treatment, 41(1), 1. https://doi.org/10.4143/crt.2009.41.1.1CrossRef

Wilczewska, A., Niemirowicz, K., Markiewicz, K., & Car, H. (2012). Nanoparticles as drug delivery systems. Pharmacological Reports, 64(5), 1020–1037. https://doi.org/10.1016/s1734-1140(12)70901-5CrossRef

Wilsker, D., Barrett, A., Dull, A., Lawrence, S., Hollingshead, M., Chen, A., et al. (2019). Evaluation of pharmacodynamic responses to cancer therapeutic agents using DNA damage markers. Clinical Cancer Research, 25(10), 3084–3095. https://doi.org/10.1158/1078-0432.ccr-18-2523CrossRef

Zhang, J., Li, S., & Li, X. (2009). Polymeric nano-assemblies as emerging delivery carriers for therapeutic applications: A review of recent patents. Recent Patents on Nanotechnology, 3(3), 225–231. https://doi.org/10.2174/187221009789177803CrossRef

Zimmerman, H. (1999). Hepatotoxicity. Lippincott Williams & Wilkins.

Titel: Controlled Delivery and Reduced Side Effects of Anticancer Drugs Complexed with Polymeric Nanocarrier
verfasst von: Lesya Kobylinska
Nataliya Mitina
Alexander Zaichenko
Rostyslav Stoika
Verlag: Springer International Publishing
Buch: Biomedical Nanomaterials
Print ISBN: 978-3-030-76234-6

Electronic ISBN: 978-3-030-76235-3

Copyright-Jahr: 2022
DOI: https://doi.org/10.1007/978-3-030-76235-3_5

Neuer Inhalt

Bildnachweise

VDI-Icon, Profil Icon, inhalt2, Springer Professional Modul/© Springer Fachmedien Wiesbaden GmbH, Nachhaltigkeitsaward Key Visual/© Cometis AG/Global ESG Monitor | Daniel Rupp | Generiert mit KI, Search Icon, Banner Hanser, Jonas Klose/© Pine Valley Capital GmbH, Carina Kießling von der Strategieberatung Roland Berger/© Monika Walther Fotografie | ATZ, Beijing Auto Show 2024: Deutsche Hersteller wollen angreifen./© EKH-Pictures / Generated with AI / Stock.adobe.com, Zeitschrift Wissensmanagement Cover, PatentFit-Logo/© Springer Fachmedien Wiesbaden GmbH, Zukunftswerkstatt Sales Excellence 2024/© AndreyPopov / Getty Images / iStock, 2023_Antrieb/© supervisuell, ATZ-Webinar: Prototypenfreie Entwicklung durch Offline- und Driver-in-the-Loop-HiL-Tests /© (c) VI-grade

Springer Professional

Abstract

Bitte loggen Sie sich ein, um Zugang zu Ihrer Lizenz zu erhalten.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Springer Professional "Technik"

Neuer Inhalt

Bitte loggen Sie sich ein, um Zugang zu Ihrer Lizenz zu erhalten.

Bitte loggen Sie sich ein, um Zugang zu Ihrer Lizenz zu erhalten.